Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

Abstract Background Capecitabine and irinotecan combination therapy (XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer (mCRC). Recently, in the Association of Medical Oncology of the German Cancer Society (AIO) 0604 trial, tri-weekly XELIRI plus bevacizumab, with...

Full description

Bibliographic Details
Main Authors: Masahito Kotaka, Ruihua Xu, Kei Muro, Young Suk Park, Satoshi Morita, Satoru Iwasa, Hiroyuki Uetake, Tomohiro Nishina, Hiroaki Nozawa, Hiroshi Matsumoto, Kentaro Yamazaki, Sae-Won Han, Wei Wang, Joong Bae Ahn, Yanhong Deng, Sang-Hee Cho, Yi Ba, Keun-Wook Lee, Tao Zhang, Taroh Satoh, Marc E. Buyse, Baek-Yeol Ryoo, Lin Shen, Junichi Sakamoto, Tae Won Kim
Format: Article
Language:English
Published: BMC 2016-12-01
Series:Chinese Journal of Cancer
Subjects:
Metastatic colorectal cancer
Randomized phase III clinical trial
XELIRI
Bevacizumab
Second-line therapy
Online Access:http://link.springer.com/article/10.1186/s40880-016-0166-3

Internet

http://link.springer.com/article/10.1186/s40880-016-0166-3

Similar Items